Two important essays on AI in drug discovery landed in August. Both are worth your time. Both have the right intuitions. And one of them is subtly framing the wrong problem, in my opinion.
The first is the Nature Reviews Drug Discovery review by Andreas Bender, Morgan Thomas, Jack Scannell, David Shaywitz, Gian Marco Ghiandoni, Joe Greener, and colleagues: “Artificial intelligence in drug discovery — what it is, where we stand and the path forward.
In a biotech startup, an early data strategy is key to ensure public and private data remain useful and valuable. As AI hype reaches new heights, I want to emphasize that a data strategy must precede any AI strategy.
Data is the oil of the AI engine. Unfortunately, the real-world data are usually messy and not AI-ready. Without a robust data strategy, you are building an AI system on a shaky foundation.